599 related articles for article (PubMed ID: 26268399)
1. Study of Pathogens of Fungal Keratitis and the Sensitivity of Pathogenic Fungi to Therapeutic Agents with the Disk Diffusion Method.
Wang L; Wang L; Han L; Yin W
Curr Eye Res; 2015; 40(11):1095-101. PubMed ID: 26268399
[TBL] [Abstract][Full Text] [Related]
2. Fungal Keratitis: Epidemiology, Rapid Detection, and Antifungal Susceptibilities of
Manikandan P; Abdel-Hadi A; Randhir Babu Singh Y; Revathi R; Anita R; Banawas S; Bin Dukhyil AA; Alshehri B; Shobana CS; Panneer Selvam K; Narendran V
Biomed Res Int; 2019; 2019():6395840. PubMed ID: 30800674
[TBL] [Abstract][Full Text] [Related]
3. Association of pretreatment with antifungal medication and fungal resistance in the mycotic ulcer treatment trial I.
Prajna NV; Prajna L; O'Brien KS; Sun CQ; Acharya N; Lietman TM; Rose-Nussbaumer J;
JAMA Ophthalmol; 2015 Oct; 133(10):1210-1. PubMed ID: 26110254
[No Abstract] [Full Text] [Related]
4. Benefit of polyhexamethylene biguanide in Fusarium keratitis.
Behrens-Baumann W; Seibold M; Hofmüller W; Walter S; Haeberle H; Wecke T; Tammer I; Tintelnot K
Ophthalmic Res; 2012; 48(4):171-6. PubMed ID: 22710976
[TBL] [Abstract][Full Text] [Related]
5. Necessity to identify the causative agent for appropriate treatment in fungal corneal ulcer: an in vitro study.
Gupta MK; Chandra A; Prakash P; Tilak R
J Mycol Med; 2018 Mar; 28(1):201-205. PubMed ID: 29398639
[TBL] [Abstract][Full Text] [Related]
6. Antimicrobial susceptibility of Fusarium, Aspergillus, and other filamentous fungi isolated from keratitis.
Lalitha P; Shapiro BL; Srinivasan M; Prajna NV; Acharya NR; Fothergill AW; Ruiz J; Chidambaram JD; Maxey KJ; Hong KC; McLeod SD; Lietman TM
Arch Ophthalmol; 2007 Jun; 125(6):789-93. PubMed ID: 17562990
[TBL] [Abstract][Full Text] [Related]
7. Natamycin and voriconazole in Fusarium and Aspergillus keratitis: subgroup analysis of a randomised controlled trial.
Prajna VN; Lalitha PS; Mascarenhas J; Krishnan T; Srinivasan M; Vaitilingam CM; Oldenburg CE; Sy A; Keenan JD; Porco TC; Acharya NR; Lietman TM
Br J Ophthalmol; 2012 Nov; 96(11):1440-1. PubMed ID: 22914503
[No Abstract] [Full Text] [Related]
8. Identification and Characterization of Fusarium proliferatum, a New Species of Fungi that Cause Fungal Keratitis.
Sun S; Lui Q; Han L; Ma Q; He S; Li X; Zhang H; Zhang J; Liu X; Wang L
Sci Rep; 2018 Mar; 8(1):4859. PubMed ID: 29559666
[TBL] [Abstract][Full Text] [Related]
9. In vitro susceptibility of filamentous fungal isolates from a corneal ulcer clinical trial.
Lalitha P; Sun CQ; Prajna NV; Karpagam R; Geetha M; O'Brien KS; Cevallos V; McLeod SD; Acharya NR; Lietman TM;
Am J Ophthalmol; 2014 Feb; 157(2):318-26. PubMed ID: 24439440
[TBL] [Abstract][Full Text] [Related]
10. Natamycin and Azithromycin Are Synergistic
Guo H; Zhou L; He Y; Gao C; Han L; Xu Y
Antimicrob Agents Chemother; 2018 Jul; 62(7):. PubMed ID: 29735563
[TBL] [Abstract][Full Text] [Related]
11. Antifungal susceptibility for common pathogens of fungal keratitis in Shandong Province, China.
Xie L; Zhai H; Zhao J; Sun S; Shi W; Dong X
Am J Ophthalmol; 2008 Aug; 146(2):260-265. PubMed ID: 18547535
[TBL] [Abstract][Full Text] [Related]
12. Voriconazole versus natamycin as primary treatment in fungal corneal ulcers.
Arora R; Gupta D; Goyal J; Kaur R
Clin Exp Ophthalmol; 2011 Jul; 39(5):434-40. PubMed ID: 21105974
[TBL] [Abstract][Full Text] [Related]
13. Antimicrobial susceptibility patterns of fungi isolated from horses with ulcerative keratomycosis.
Brooks DE; Andrew SE; Dillavou CL; Ellis G; Kubilis PS
Am J Vet Res; 1998 Feb; 59(2):138-42. PubMed ID: 9492925
[TBL] [Abstract][Full Text] [Related]
14. Adjunctive Oral Voriconazole Treatment of Fusarium Keratitis: A Secondary Analysis From the Mycotic Ulcer Treatment Trial II.
Prajna NV; Krishnan T; Rajaraman R; Patel S; Shah R; Srinivasan M; Devi L; Das M; Ray KJ; O'Brien KS; Oldenburg CE; McLeod SD; Zegans ME; Acharya NR; Lietman TM; Rose-Nussbaumer J;
JAMA Ophthalmol; 2017 Jun; 135(6):520-525. PubMed ID: 28426856
[TBL] [Abstract][Full Text] [Related]
15. Association between in vitro susceptibility to natamycin and voriconazole and clinical outcomes in fungal keratitis.
Sun CQ; Lalitha P; Prajna NV; Karpagam R; Geetha M; O'Brien KS; Oldenburg CE; Ray KJ; McLeod SD; Acharya NR; Lietman TM;
Ophthalmology; 2014 Aug; 121(8):1495-500.e1. PubMed ID: 24746358
[TBL] [Abstract][Full Text] [Related]
16. The mycotic ulcer treatment trial: a randomized trial comparing natamycin vs voriconazole.
Prajna NV; Krishnan T; Mascarenhas J; Rajaraman R; Prajna L; Srinivasan M; Raghavan A; Oldenburg CE; Ray KJ; Zegans ME; McLeod SD; Porco TC; Acharya NR; Lietman TM;
JAMA Ophthalmol; 2013 Apr; 131(4):422-9. PubMed ID: 23710492
[TBL] [Abstract][Full Text] [Related]
17. In vitro antifungal activity of silver nanoparticles against ocular pathogenic filamentous fungi.
Xu Y; Gao C; Li X; He Y; Zhou L; Pang G; Sun S
J Ocul Pharmacol Ther; 2013 Mar; 29(2):270-4. PubMed ID: 23410063
[TBL] [Abstract][Full Text] [Related]
18. In vitro susceptibility patterns of Aspergillus and Fusarium species isolated from equine ulcerative keratomycosis cases in the midwestern and southern United States with inclusion of the new antifungal agent voriconazole.
Pearce JW; Giuliano EA; Moore CP
Vet Ophthalmol; 2009; 12(5):318-24. PubMed ID: 19751493
[TBL] [Abstract][Full Text] [Related]
19. Organism, minimum inhibitory concentration, and outcome in a fungal corneal ulcer clinical trial.
Lalitha P; Prajna NV; Oldenburg CE; Srinivasan M; Krishnan T; Mascarenhas J; Vaitilingam CM; McLeod SD; Zegans ME; Porco TC; Acharya NR; Lietman TM
Cornea; 2012 Jun; 31(6):662-7. PubMed ID: 22333662
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic response time of topical voriconazole 1% and intrastromal voriconazole 0.05% versus topical natamycin 5% monotherapy in Fusarium keratitis in rabbit.
Edwar L; Janna YM; Rozaliyani A; Louisa M
Mycoses; 2020 Oct; 63(10):1128-1132. PubMed ID: 32780874
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
